EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive search to yield a commercial partner. The company is already facing a massive cash crunch and without a partner, it is unable to sustain the development cost of reni-cel. The candidate was evaluated in a phase I/II/III RUBY study and a phase I/II EdiTHAL study for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), respectively. Per Editas, it plans to work closely with the clinical study sites, regulators and other parties to determine the path forward for patients enrolled in the RUBY and EdiTHAL studies. The abandonment of these studies has significantly delayed the company's hopes of earning any revenues. As part of its strategic reprioritization efforts, Editas announced that it will now focus its resources on in vivo (within the living organism) pipeline development. The company aims to accelerate its intent to achieve in
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- 1 big new Green Flag for CRISPR Therapeutics' Stock [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $86.00 price target on the stock.MarketBeat
- Capsida Biotherapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Celebrating a Milestone: Engineering Tomorrow Reaches 1 Million Students [Yahoo! Finance]Yahoo! Finance
- 2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/5/24 - Beat
CRSP
Sec Filings
- 12/10/24 - Form SC
- 12/4/24 - Form 4
- 11/13/24 - Form 4
- CRSP's page on the SEC website